88 related articles for article (PubMed ID: 3659004)
1. Plasma hormone levels before and after orchiectomy in prostate cancer patients.
Fiet J; Villette JM; Bertagna C; de Géry A; Hucher M; Husson JM; Raynaud JP
Prog Clin Biol Res; 1987; 243A():33-44. PubMed ID: 3659004
[No Abstract] [Full Text] [Related]
2. The endocrine profiles in men with localized and locally advanced prostate cancer treated with radical prostatectomy.
Heracek J; Urban M; Sachova J; Kuncova J; Eis V; Mandys V; Hampl R; Starka L
Neuro Endocrinol Lett; 2007 Feb; 28(1):45-51. PubMed ID: 17277727
[TBL] [Abstract][Full Text] [Related]
3. Pretreatment hormone levels in prostatic cancer.
Haapiainen R; Rannikko S; Alfthan O; Adlercreutz H
Scand J Urol Nephrol Suppl; 1988; 110():137-43. PubMed ID: 3187401
[TBL] [Abstract][Full Text] [Related]
4. [Plasma prolactin in different age groups (author's transl)].
Weiske WH; Frick J
Padiatr Padol Suppl; 1977; (5):49-55. PubMed ID: 917576
[TBL] [Abstract][Full Text] [Related]
5. Influence of radical prostatectomy on serum hormone levels.
Miller LR; Partin AW; Chan DW; Bruzek DJ; Dobs AS; Epstein JI; Walsh PC
J Urol; 1998 Aug; 160(2):449-53. PubMed ID: 9679896
[TBL] [Abstract][Full Text] [Related]
6. [Change of serum adrenal androgens in prostatic cancer patients after bilateral orchidectomy or LHRH agonist treatment].
Oka H; Negoro H; Sugino Y; Iwamura H; Moroi S; Kawakita M
Hinyokika Kiyo; 2003 Sep; 49(9):521-5. PubMed ID: 14598689
[TBL] [Abstract][Full Text] [Related]
7. [The prognostic significance of prolactin in prostate cancer].
Røhl HF; Andersen OP
Ugeskr Laeger; 1987 Dec; 149(50):3402-3. PubMed ID: 3433541
[No Abstract] [Full Text] [Related]
8. Serological precursors of cancer: serum hormones and risk of subsequent prostate cancer.
Hsing AW; Comstock GW
Cancer Epidemiol Biomarkers Prev; 1993; 2(1):27-32. PubMed ID: 8420607
[TBL] [Abstract][Full Text] [Related]
9. Hormone levels following surgical and medical castration: defining optimal androgen suppression.
Schweizer MT; Hancock ML; Getzenberg RH; Yu EY
Asian J Androl; 2018; 20(4):405-406. PubMed ID: 29111538
[No Abstract] [Full Text] [Related]
10. Hormone concentrations in postmenopausal patients with breast cancer.
Jones MK; Ramsay ID; Booth M; Collins WP
Clin Oncol; 1977 Jun; 3(2):177-81. PubMed ID: 872471
[No Abstract] [Full Text] [Related]
11. [Hormone determinations in andrology].
Frick J
Andrologia; 1980; 12(3):211-8. PubMed ID: 6778255
[TBL] [Abstract][Full Text] [Related]
12. Comparison of subcapsular and total orchiectomy for treatment of metastatic prostate cancer.
Zhang XZ; Donovan MP; Williams BT; Mohler JL
Urology; 1996 Mar; 47(3):402-4. PubMed ID: 8633409
[TBL] [Abstract][Full Text] [Related]
13. Baldness, benign prostate hyperplasia, prostate cancer and androgen levels.
Faydaci G; Bilal E; Necmettin P; Fatih T; Asuman O; Uğur K
Aging Male; 2008 Dec; 11(4):189-92. PubMed ID: 19172550
[TBL] [Abstract][Full Text] [Related]
14. Tissue and serum levels of principal androgens in benign prostatic hyperplasia and prostate cancer.
Heracek J; Hampl R; Hill M; Starka L; Sachova J; Kuncova J; Eis V; Urban M; Mandys V
Steroids; 2007 Apr; 72(4):375-80. PubMed ID: 17368496
[TBL] [Abstract][Full Text] [Related]
15. Bilateral orchiectomy in the management of stage D-2 prostate cancer.
Guinan P; Firfer R; Targonski P; Rubenstein M
Int Surg; 1993; 78(1):73-5. PubMed ID: 8473090
[TBL] [Abstract][Full Text] [Related]
16. Measurements of prolactin and androgens in patients with prostatic disease.
Saroff J; Kirdani RY; Chu TM; Wajsman Z; Murphy GP
Surg Forum; 1977; 28():568-9. PubMed ID: 83009
[No Abstract] [Full Text] [Related]
17. Testosterone levels in benign prostatic hypertrophy and prostate cancer.
Mearini L; Costantini E; Zucchi A; Mearini E; Bini V; Cottini E; Porena M
Urol Int; 2008; 80(2):134-40. PubMed ID: 18362481
[TBL] [Abstract][Full Text] [Related]
18. Intra-prostatic androgen levels during various androgen-blockade regimens.
Nishiyama T
Best Pract Res Clin Endocrinol Metab; 2008 Apr; 22(2):229-41. PubMed ID: 18471782
[TBL] [Abstract][Full Text] [Related]
19. Changes in prostate-specific antigen and hormone levels following withdrawal of prolonged androgen ablation for prostate cancer.
Egawa S; Okusa H; Matsumoto K; Suyama K; Baba S
Prostate Cancer Prostatic Dis; 2003; 6(3):245-9. PubMed ID: 12970730
[TBL] [Abstract][Full Text] [Related]
20. [Role of hormonal profile in adjusting therapy for prostate cancer].
Granov AM; Molchanov OE; Karelin MI
Vopr Onkol; 2008; 54(4):457-62. PubMed ID: 18942400
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
